SPRO Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of -271.3% compared to Spero Therapeutics's net margin of 14.45%. Spero Therapeutics's return on equity of -108.26% beat Boston Scientific's return on equity of 9.57%.

Spero Therapeutics has a consensus price target of $5.00, signalling upside risk potential of 73.61%. On the other hand Boston Scientific has an analysts' consensus of $117.14 which suggests that it could grow by 12.51%. Given that Spero Therapeutics has higher upside potential than Boston Scientific, analysts believe Spero Therapeutics is more attractive than Boston Scientific.

Spero Therapeutics has a beta of 1.313, which suggesting that the stock is 31.286% more volatile than S&P 500. In comparison Boston Scientific has a beta of 0.681, suggesting its less volatile than the S&P 500 by 31.908%.

Spero Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spero Therapeutics pays -- of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.

Spero Therapeutics quarterly revenues are $5.1M, which are smaller than Boston Scientific quarterly revenues of $4.7B. Spero Therapeutics's net income of -$13.9M is lower than Boston Scientific's net income of $674M. Notably, Spero Therapeutics's price-to-earnings ratio is 10.75x while Boston Scientific's PE ratio is 76.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spero Therapeutics is 5.55x versus 8.83x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Dare Bioscience has a net margin of -271.3% compared to Spero Therapeutics's net margin of -17219.13%. Spero Therapeutics's return on equity of -108.26% beat Dare Bioscience's return on equity of --.

Spero Therapeutics has a consensus price target of $5.00, signalling upside risk potential of 73.61%. On the other hand Dare Bioscience has an analysts' consensus of $13.00 which suggests that it could grow by 386.89%. Given that Dare Bioscience has higher upside potential than Spero Therapeutics, analysts believe Dare Bioscience is more attractive than Spero Therapeutics.

Spero Therapeutics has a beta of 1.313, which suggesting that the stock is 31.286% more volatile than S&P 500. In comparison Dare Bioscience has a beta of 1.202, suggesting its more volatile than the S&P 500 by 20.169%.

Spero Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dare Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spero Therapeutics pays -- of its earnings as a dividend. Dare Bioscience pays out -- of its earnings as a dividend.

Spero Therapeutics quarterly revenues are $5.1M, which are larger than Dare Bioscience quarterly revenues of $25.4K. Spero Therapeutics's net income of -$13.9M is lower than Dare Bioscience's net income of -$4.4M. Notably, Spero Therapeutics's price-to-earnings ratio is 10.75x while Dare Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spero Therapeutics is 5.55x versus 870.60x for Dare Bioscience. Usually stocks with elevated PS ratios are considered overvalued.

Macrogenics has a net margin of -271.3% compared to Spero Therapeutics's net margin of -311.07%. Spero Therapeutics's return on equity of -108.26% beat Macrogenics's return on equity of -58.23%.

Spero Therapeutics has a consensus price target of $5.00, signalling upside risk potential of 73.61%. On the other hand Macrogenics has an analysts' consensus of $4.20 which suggests that it could grow by 213.43%. Given that Macrogenics has higher upside potential than Spero Therapeutics, analysts believe Macrogenics is more attractive than Spero Therapeutics.

Spero Therapeutics has a beta of 1.313, which suggesting that the stock is 31.286% more volatile than S&P 500. In comparison Macrogenics has a beta of 1.652, suggesting its more volatile than the S&P 500 by 65.244%.

Spero Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Macrogenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spero Therapeutics pays -- of its earnings as a dividend. Macrogenics pays out -- of its earnings as a dividend.

Spero Therapeutics quarterly revenues are $5.1M, which are smaller than Macrogenics quarterly revenues of $13.2M. Spero Therapeutics's net income of -$13.9M is higher than Macrogenics's net income of -$41M. Notably, Spero Therapeutics's price-to-earnings ratio is 10.75x while Macrogenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spero Therapeutics is 5.55x versus 0.55x for Macrogenics. Usually stocks with elevated PS ratios are considered overvalued.

Ocular Therapeutix has a net margin of -271.3% compared to Spero Therapeutics's net margin of -598.74%. Spero Therapeutics's return on equity of -108.26% beat Ocular Therapeutix's return on equity of -56.05%.

Spero Therapeutics has a consensus price target of $5.00, signalling upside risk potential of 73.61%. On the other hand Ocular Therapeutix has an analysts' consensus of $17.42 which suggests that it could grow by 91.6%. Given that Ocular Therapeutix has higher upside potential than Spero Therapeutics, analysts believe Ocular Therapeutix is more attractive than Spero Therapeutics.

Spero Therapeutics has a beta of 1.313, which suggesting that the stock is 31.286% more volatile than S&P 500. In comparison Ocular Therapeutix has a beta of 1.416, suggesting its more volatile than the S&P 500 by 41.629%.

Spero Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocular Therapeutix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spero Therapeutics pays -- of its earnings as a dividend. Ocular Therapeutix pays out -- of its earnings as a dividend.

Spero Therapeutics quarterly revenues are $5.1M, which are smaller than Ocular Therapeutix quarterly revenues of $10.7M. Spero Therapeutics's net income of -$13.9M is higher than Ocular Therapeutix's net income of -$64.1M. Notably, Spero Therapeutics's price-to-earnings ratio is 10.75x while Ocular Therapeutix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spero Therapeutics is 5.55x versus 25.54x for Ocular Therapeutix. Usually stocks with elevated PS ratios are considered overvalued.